EQUITY RESEARCH Healthcare | European Pharmaceuticals | 23 July 2010 ACTELION To be or not to be a biotech company Initiating with a 1-Overweight rating – generic risk…

1. AbstrActs _257 New Treatment and Orphan Drug DevelopmentAccess to the diagnosis and treatment of patients with mucopolysaccharidosis type I in RomaniaAuthors : Dr Camelia…

Slide 1Impact of Velaglucerase Alfa Therapy on Bone Marrow Burden Score in Adults with Type 1 Gaucher Disease: 7-Year Experience Deborah Elstein; 1 Andrew H. Haims; 2 David…

Slide 1ERT IN JUVENILE AND ADULT GLYCOGENOSIS TYPE 2 Bruno Bembi – Giovanni Ciana – Andrea Dardis Unità di Malattie Metaboliche-Laboratorio di Malattie Rare Istituto…

1.©2005 FASEBThe FASEB Journal express article 10.1096/fj.05-3826fje. Published online June 29, 2005. Enzyme replacement therapy results in substantial improvements in early…

1. Late Outcomes of Cord Blood Transplantation for Patients with Hurler Syndrome Jaap J Boelens June 2013 (11th CB symposium San Fransisco) 2. I have no Conflict of Interest…

Digestion & absorption of lipids Digestion & absorption of lipids 3/9/2015 3:06 PM Dr. Vijay Marakala, MBBS, MD. Senior Lecturer BIOCHEMISTRY IMS, MSU. DIETARY LIPIDS…

Slide 1 Fabry Disease By Farshid mokhberi Shahid beheshti University of Medical Sciences Fabry disease Definition: Fabry disease (also known as Fabry's disease, Anderson-Fabry…

1. Global Gaucher Disease Market 2015-2019 www.technavio.com [email protected] 2. USA – CANADA – UK – CHINA – INDIA Global Gaucher Disease Market 2015-2019 The…

Slide 1 Whole body MRI technique in early treated non-neuronopathic patients with enzyme replacement therapy at least eight years Larissa Moos, Jörg Reinke, Miriam Brixius-Huth,…